Ann: Phase 2 blood cancer trial fully recruited, page-12

Informative Presentation
15th Patient has been Dosed
Open Label Trial with Interim Results ( current results "Safety Profile is similar to the Phase I " no serious adverse effects to date).

1st week of December Presentation of Interim Data at the American Society of Hematology where 30,000 Specialists Attend.

1st Q 2025 Phase II data to be presented to the FDA ,, $$$$

Whats is important to note is that we now have a Biotech Fund Invested with us ,,, the amount of DD is significant when a fund applies $$$$$ as Funds need to make a return to their Investors so it signals to the market that SNT is highly likely to increase significantly in value,, also a Fund is as only good as its reputation and results ,,, these guys don't just throw money into companies ,,, TBH it was a confidence boost PLUS SNT are still going to pursue the funds owing to the Company the placement was swift and necessary.. and in todays economic climate demonstrates SNT is a significant Investment opportunity NZT